Difference between revisions of "Baker Pharmaceuticals"
Sarna News
| (11 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
| − | '''Baker Pharmaceuticals''' | + | {{InfoBoxCorporation |
| + | | image = | ||
| + | | Founded = | ||
| + | | Dissolved = | ||
| + | | Previous Names = | ||
| + | | headquarters = New Benner<br/>([[Baker 3]])<ref name=HSTLC-142/> | ||
| + | | leadership = [[CEO of Baker Pharmaceuticals|CEO]] | ||
| + | | products = | ||
| + | | Parent Corporation = | ||
| + | | Division = | ||
| + | }} | ||
| + | '''Baker Pharmaceuticals''' was a pharmaceutical company in the [[Lyran Commonwealth]], with its assets eventually acquired by the mammoth [[Nashan Diversified]]. <ref name=HSTLC-142>''House Steiner (The Lyran Commonwealth)'', p. 142 "Socioeconomics - Other Major Commonwealth Industries - Baker Pharmaceuticals"</ref> <ref name=HHS-134>''Handbook: House Steiner'', p. 134 - "Economics - Major Industries- Nashan Diversified".</ref> | ||
==Company Profile== | ==Company Profile== | ||
| − | '''Commonwealth Stock Exchange Symbol:''' BakPhar | + | '''Commonwealth Stock Exchange Symbol:''' BakPhar. <ref name=HSTLC-142/> |
| − | ''' | + | '''President/CEO:''' [[John Sleeth]] (circa 3024).<ref name=HSTLC-142/> |
| − | + | ==Overview== | |
| + | Baker Pharmaceuticals had been in business with the Lyran Commonwealth for many years but encountered serious financial and personnel problems after losing a 300-million-[[Kroner|S-Bill]] lawsuit in [[3023]] when a batch of their synthetic molecular antibodies went toxic, killing over 100 [[Lyran Commonwealth Armed Forces]] soldiers. Like a shark smelling blood in the water, Nashan Diversified launched a takeover attempt in [[3024]], which Baker CEO John Sleeth attempted to resist by ordering his brokers to buy back all public Baker stocks at a substantially higher price than Nashan's offer.<ref name=HSTLC-142/> | ||
| − | + | While saving the company in the short-term, the heavy financial burden of the buy-back forced BP to cut costs and let go staff, leaving it in dire straits with many observers questioning if the company would survive beyond [[3025]].<ref name=HSTLC-142/> Nashan would ultimately succeed in acquiring Baker Pharmaceuticals, but rather than reorganize and integrate the company's Baker 3 headquarters into the Nashan family, Nashan chose to virtually liquidate BP and transfer its remaining assets to Nashan's newer [[Donegal]] offices to serve as its '''Nashan Pharmaceuticals''' division.<ref name=HHS-134/> | |
==References== | ==References== | ||
| Line 15: | Line 27: | ||
==Bibliography== | ==Bibliography== | ||
| + | *''[[Handbook: House Steiner]]'' | ||
*''[[House Steiner (The Lyran Commonwealth)]]'' | *''[[House Steiner (The Lyran Commonwealth)]]'' | ||
| − | [[Category: | + | [[Category:Lyran Commonwealth Corporations]] |
Latest revision as of 08:23, 25 November 2023
Baker Pharmaceuticals | |
|---|---|
| Corporation Profile | |
| Headquarters | New Benner (Baker 3)[1] |
| Leadership | CEO |
Baker Pharmaceuticals was a pharmaceutical company in the Lyran Commonwealth, with its assets eventually acquired by the mammoth Nashan Diversified. [1] [2]
Company Profile[edit]
Commonwealth Stock Exchange Symbol: BakPhar. [1]
President/CEO: John Sleeth (circa 3024).[1]
Overview[edit]
Baker Pharmaceuticals had been in business with the Lyran Commonwealth for many years but encountered serious financial and personnel problems after losing a 300-million-S-Bill lawsuit in 3023 when a batch of their synthetic molecular antibodies went toxic, killing over 100 Lyran Commonwealth Armed Forces soldiers. Like a shark smelling blood in the water, Nashan Diversified launched a takeover attempt in 3024, which Baker CEO John Sleeth attempted to resist by ordering his brokers to buy back all public Baker stocks at a substantially higher price than Nashan's offer.[1]
While saving the company in the short-term, the heavy financial burden of the buy-back forced BP to cut costs and let go staff, leaving it in dire straits with many observers questioning if the company would survive beyond 3025.[1] Nashan would ultimately succeed in acquiring Baker Pharmaceuticals, but rather than reorganize and integrate the company's Baker 3 headquarters into the Nashan family, Nashan chose to virtually liquidate BP and transfer its remaining assets to Nashan's newer Donegal offices to serve as its Nashan Pharmaceuticals division.[2]